Tonix Pharmaceuticals Says World Health Organization's Preferred Target Product Profile, Aligns With The Characteristics Of TNX-801 (Horsepox, Live Virus) Vaccine, Which Is Being Developed For Preventing Mpox
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals announced that the World Health Organization's preferred target product profile aligns with the characteristics of their TNX-801 vaccine, which is being developed to prevent Mpox. This alignment could potentially enhance the vaccine's marketability and acceptance.
September 16, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals' TNX-801 vaccine aligns with WHO's preferred target product profile for Mpox prevention, which could enhance its marketability and acceptance.
The alignment of TNX-801 with WHO's preferred target product profile suggests that the vaccine meets important international standards, which could lead to increased acceptance and demand. This is likely to positively impact Tonix Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90